Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Technique Described for Detection of KRAS Mutations in Pathology Specimens

By LabMedica International staff writers
Posted on 20 Jun 2016
A recent paper described a rapid and inexpensive method for detecting KRAS mutations in clinical biopsy specimens of lung and colorectal cancers.

KRAS mutations have emerged as powerful predictors of response to targeted therapies in the treatment of lung and colorectal cancers; thus, prospective KRAS genotyping is essential for selecting appropriate treatment. Conventional mutation testing technologies are not ideal for routine clinical screening, as they often involve complex, time-consuming processes and/or costly instrumentation.

Investigators at the University of Virginia (Charlottesville, USA) recently described a method that uses hybridization-induced aggregation (HIA) technology for mutation detection (HIAMD), which enables the detection of common KRAS mutations in less than 10 minutes following PCR amplification.

The method is an extension of hybridization-induced aggregation (HIA) technology, whereby the hybridization of a specific DNA target to a pair of oligonucleotide probes immobilized on the surface of microbeads, tethers the microbeads together and induces aggregation. A digital image of the hybridization micro well is used for quantifying the extent of aggregation in terms of image saturation, which allows for a quantitative representation of hybridization efficiency.

The HIAMD method uses samples processed according to current clinical protocols and is compatible with the clinical laboratory workflow for sample preparation, which includes nucleic acid extraction and PCR amplification. After amplification, HIAMD analysis for the detection of all common KRAS mutations (located in codons 12 and 13) is complete in less than10 minutes, which includes approximately three minutes for thermal denaturation and snap-cool, approximately one minute for pipetting the reagents (sample, buffer, and beads) onto the chip, two minutes for the hybridization assay, and approximately three minutes for image analysis. Sequencing analysis, on the other hand, requires further sample preparation, including a tedious PCR cleanup step, and has a turnaround time in the order of days. The simple instrumentation needed for HIAMD keeps the method very low in cost (approximately 2500 USD for all equipment, compared to approximately 100,000 USD for sequencing instrumentation).

The investigators evaluated the clinical utility of the HIAMD method for the analysis of 20 lung and colon tumor pathology specimens. They observed a 100% correlation between the KRAS mutation statuses determined by HIAMD and by classical sequencing. In addition, they were able to detect KRAS mutations in a background of 75% wild-type DNA—a finding consistent with that reported for sequencing.

"These results indicate the validity of HIAMD as a mutation-testing technology suitable for practical clinical testing," said senior author Dr. Kimberly A. Kelly, professor of biomedical engineering at the University of Virginia. "Importantly, the analysis is performed in a manner that is both rapid and cost effective. The current direction of clinical oncology research suggests that a technology such as HIAMD will continue to be a highly relevant and valued analytical tool for the facilitation of individualized therapeutic strategies, and the successes here indicate the potential to apply this technology for the routine analysis of other important genetic markers."

"Targeted therapies are a growing trend in basic and clinical cancer research, and for good reason - the potential for improved treatment outcomes and cost savings is tremendous," said Dr. Kelly. "However, the effective implementation of a targeted therapeutic regime requires a practical means for preemptive molecular characterization of the cancer. In an effort to fulfill the unmet clinical demand for a methodology amenable to the requirements of routine testing, we developed a novel approach that provides simple, rapid, and inexpensive detection of point mutations."

The paper was published in the June 8, 2016, online edition of The Journal of Molecular Diagnostics.

Related Links:
University of Virginia



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Troponin I Test
Quidel Triage Troponin I Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.